CMPX logo

CMPXCompass Therapeutics Inc

$1.86
$0.14
(6.80%)
Today
Closed $1.92
$0.06
(3.13%)
Overnight
Updated: 08:18 PM EDT
EarningsAug 14
Mkt Cap$370.98M
Vol3.52M
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
News Placeholder
Canaccord Genuity Group Lowers Compass Therapeutics (NASDAQ:CMPX) Price Target to $7.00
Canaccord Genuity Group dropped their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday...
MarketBeat
News Placeholder
Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX)
Citizens Jmp restated a "market outperform" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday...
MarketBeat
News Placeholder
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low - What's Next?
Compass Therapeutics (NASDAQ:CMPX) Reaches New 52-Week Low - Here's Why...
MarketBeat
News Placeholder
Compass Therapeutics Touts Stunning PFS Win in COMPANION-002 as Crossover Muddy OS Data
Compass Therapeutics (NASDAQ:CMPX) executives highlighted what CEO and Vice Chair Dr. Thomas Schuetz called absolutely stunning progression-free survival results from the company's phase II/III...
MarketBeat
News Placeholder
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates.read more...
Benzinga
News Placeholder
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital
D. Boral Capital restated a "buy" rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Monday...
MarketBeat
News Placeholder
This Small-Cap Biotech Is Gearing Up For A Make-Or-Break Cancer Drug Data Drop
The biotech firm is set to report topline data on secondary endpoints from its Phase 2/3 trial for advanced biliary tract cancer on Monday.
Stocktwits
News Placeholder
M&T Bank Corp Makes New $4.10 Million Investment in Compass Therapeutics, Inc. $CMPX
M&T Bank Corp bought a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 764,229 shares of the company's stoc...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.